Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 92

1.

Long-term safety and outcome of fludarabine, cyclophosphamide and mitoxantrone (FCM) regimen in previously untreated patients with advanced follicular lymphoma: 12 years follow-up of a phase 2 trial.

Magnano L, Montoto S, González-Barca E, Briones J, Sancho JM, Muntañola A, Salar A, Besalduch J, Escoda L, Moreno C, Domingo-Domenech E, Estany C, Oriol A, Altés A, Pedro C, Gardella S, Asensio A, Vivancos P, Fernández de Sevilla A, Ribera JM, Colomer D, Campo E, López-Guillermo A.

Ann Hematol. 2017 Apr;96(4):639-646. doi: 10.1007/s00277-017-2920-2. Epub 2017 Jan 18.

PMID:
28101592
2.

Critical analysis of the stringent complete response in multiple myeloma: contribution of sFLC and bone marrow clonality.

Martínez-López J, Paiva B, López-Anglada L, Mateos MV, Cedena T, Vidríales MB, Sáez-Gómez MA, Contreras T, Oriol A, Rapado I, Teruel AI, Cordón L, Blanchard MJ, Bengoechea E, Palomera L, de Arriba F, Cueto-Felgueroso C, Orfao A, Bladé J, San Miguel JF, Lahuerta JJ; Spanish Multiple Myeloma Group / Program for the Study of Malignant Blood Diseases Therapeutics (GEM / PETHEMA) Cooperative Study Group.

Blood. 2015 Aug 13;126(7):858-62. doi: 10.1182/blood-2015-04-638742. Epub 2015 Jun 18.

3.

Differential Impact of Relative Dose-Intensity Reductions in Diffuse Large B-Cell Lymphoma Treated with R-CHOP21 or R-CHOP14.

Gutiérrez A, Bento L, Bautista-Gili AM, Garcia F, Martinez-Serra J, Sanchez B, Martorell C, Gines J, Garcia L, Gimeno E, Ferraro M, Del Campo R, Bargay J, Perez A, Vercher J, Scaff M, Pacheco A, Ballester C, Garcia F, Ramos R, Salar A, Besalduch J.

PLoS One. 2015 Apr 24;10(4):e0123978. doi: 10.1371/journal.pone.0123978. eCollection 2015.

4.

Radiation therapy overcomes adverse prognostic role of cyclooxygenase-2 expression on Reed-Sternberg cells in early Hodgkin lymphoma.

Mestre F, Gutiérrez A, Rodriguez J, Ramos R, Garcia JF, Martinez-Serra J, Casasus M, Nicolau C, Bento L, Herraez I, Lopez-Perezagua P, Daumal J, Besalduch J.

Int J Radiat Oncol Biol Phys. 2015 May 1;92(1):84-90. doi: 10.1016/j.ijrobp.2014.10.004. Epub 2014 Dec 2.

PMID:
25475251
5.

Gemcitabine and oxaliplatinum: an effective regimen in patients with refractory and relapsing Hodgkin lymphoma.

Gutierrez A, Rodriguez J, Martinez-Serra J, Gines J, Paredes P, Garcia F, Vercher J, Balanzat J, Del Campo R, Galan P, Morey M, Sampol A, Novo A, Bento L, García L, Bargay J, Besalduch J.

Onco Targets Ther. 2014 Nov 13;7:2093-100. doi: 10.2147/OTT.S70264. eCollection 2014.

6.

Chronic myeloid leukemia with an e1a3 BCR-ABL fusion protein: transformation to lymphoid blast crisis.

Martinez-Serra J, Del Campo R, Gutierrez A, Antich JL, Ginard M, Durán MA, Bento L, Ros T, Amat JC, Vidal C, Iglesias JF, Orlinska I, Besalduch J.

Biomark Res. 2014 Aug 14;2:14. doi: 10.1186/2050-7771-2-14. eCollection 2014.

7.

Fluorescence resonance energy transfer-based real-time polymerase chain reaction method without DNA extraction for the genotyping of F5, F2, F12, MTHFR, and HFE.

Martinez-Serra J, Robles J, Nicolàs A, Gutierrez A, Ros T, Amat JC, Alemany R, Vögler O, Abelló A, Noguera A, Besalduch J.

J Blood Med. 2014 Jun 25;5:99-106. doi: 10.2147/JBM.S64976. eCollection 2014.

8.

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies.

Martinez-Serra J, Gutierrez A, Muñoz-Capó S, Navarro-Palou M, Ros T, Amat JC, Lopez B, Marcus TF, Fueyo L, Suquia AG, Gines J, Rubio F, Ramos R, Besalduch J.

Onco Targets Ther. 2014 Jun 12;7:985-94. doi: 10.2147/OTT.S62887. eCollection 2014.

9.

Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia.

Bernués M, Durán MA, Puget G, Iglesias J, Galán P, Vercher FJ, Besalduch J, Rosell J.

Anticancer Res. 2014 May;34(5):2311-4.

PMID:
24778036
10.

Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.

Martinez-Lopez J, Fernández-Redondo E, García-Sánz R, Montalbán MA, Martínez-Sánchez P, Pavia B, Mateos MV, Rosiñol L, Martín M, Ayala R, Martínez R, Blanchard MJ, Alegre A, Besalduch J, Bargay J, Hernandez MT, Sarasquete ME, Sanchez-Godoy P, Fernández M, Blade J, San Miguel JF, Lahuerta JJ; GEM (Grupo Español Multidisciplinar de Melanoma)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) cooperative study group.

Br J Haematol. 2013 Dec;163(5):581-9. doi: 10.1111/bjh.12576. Epub 2013 Oct 3.

PMID:
24117042
11.

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study.

Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group.

Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.

12.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.

Blood. 2012 Aug 23;120(8):1589-96. Epub 2012 Jul 12.

13.

Outcome of Antifungal Combination Therapy for Invasive Mold Infections in Hematological Patients is Independent of the Chosen Combination.

Rojas R, Molina JR, Jarque I, Montes C, Serrano J, Sanz J, Besalduch J, Carreras E, Tomas JF, Madero L, Rubio D, Conde E, Sanz MA, Torres A.

Mediterr J Hematol Infect Dis. 2012;4(1):e2012011. doi: 10.4084/MJHID.2012.011. Epub 2012 Feb 10.

14.

Four-channel asymmetric Real-Time PCR hybridization probe assay: a rapid pre-screening method for critical BCR-ABL kinase domain mutations.

Martinez-Serra J, Gutiérrez A, Marcús TF, Soverini S, Amat JC, Navarro-Palou M, Ros T, Bex T, Ballester C, Bauça JM, SanFelix S, Novo A, Vidal C, Santos C, Besalduch J.

Clin Biochem. 2012 Mar;45(4-5):345-51. doi: 10.1016/j.clinbiochem.2011.12.026. Epub 2012 Jan 12.

PMID:
22266405
15.

Benefit from autologous stem cell transplantation in primary refractory myeloma? Different outcomes in progressive versus stable disease.

Rosiñol L, García-Sanz R, Lahuerta JJ, Hernández-García M, Granell M, de la Rubia J, Oriol A, Hernández-Ruiz B, Rayón C, Navarro I, García-Ruiz JC, Besalduch J, Gardella S, López Jiménez J, Díaz-Mediavilla J, Alegre A, San Miguel J, Bladé J; PETHEMA/Spanish Myeloma Group.

Haematologica. 2012 Apr;97(4):616-21. doi: 10.3324/haematol.2011.051441. Epub 2011 Nov 4.

16.

High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.

Mounier N, Canals C, Gisselbrecht C, Cornelissen J, Foa R, Conde E, Maertens J, Attal M, Rambaldi A, Crawley C, Luan JJ, Brune M, Wittnebel S, Cook G, van Imhoff GW, Pfreundschuh M, Sureda A; Lymphoma Working Party of European Blood and Marrow Transplantation Registry (EBMT).

Biol Blood Marrow Transplant. 2012 May;18(5):788-93. doi: 10.1016/j.bbmt.2011.10.010. Epub 2011 Oct 17.

17.

Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, Passweg J, Martino R, Valcárcel D, Besalduch J, Duarte R, León A, Pascual MJ, García-Noblejas A, López Corral L, Xicoy B, Sierra J, Schmitz N.

Haematologica. 2012 Feb;97(2):310-7. doi: 10.3324/haematol.2011.045757. Epub 2011 Oct 11.

18.

Structural rearrangements of trisomies are a risk marker of clinical progression in hyperdiploid multiple myeloma.

Alfaro R, Rosell J, Durán MA, Puget G, Besalduch J, Galán P, Vallés A, Bernués M.

Anticancer Res. 2011 May;31(5):1599-602.

PMID:
21617215
19.

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Martinez-Lopez J, Blade J, Mateos MV, Grande C, Alegre A, García-Laraña J, Sureda A, de la Rubia J, Conde E, Martinez R, de Arriba F, Viguria MC, Besalduch J, Cabrera R, Gonzalez-San Miguel JD, Guzman-Zamudio JL, Gomez del Castillo MC, Moraleda JM, García-Ruiz JC, San Miguel J, Lahuerta JJ; Grupo Español de MM; Programa para el Estudio de la Terapé utica en Hemopatía Maligna.

Blood. 2011 Jul 21;118(3):529-34. doi: 10.1182/blood-2011-01-332320. Epub 2011 Apr 11.

20.

Yondelis® (ET-743, Trabectedin) sensitizes cancer cell lines to CD95-mediated cell death: new molecular insight into the mechanism of action.

Martínez-Serra J, Maffiotte E, Martín J, Bex T, Navarro-Palou M, Ros T, Plazas JM, Vögler O, Gutiérrez A, Amat JC, Ramos R, Saus C, Ginés J, Alemany R, Diaz M, Besalduch J.

Eur J Pharmacol. 2011 May 11;658(2-3):57-64. doi: 10.1016/j.ejphar.2011.02.035. Epub 2011 Mar 1.

PMID:
21371453

Supplemental Content

Loading ...
Support Center